The Rutgers Cancer Institute of New Jersey announced it has begun a clinical trial that will examine whether an anti-malaria drug doctors are administering as an off-label use to treat the coronavirus is more effective when taken with an antibiotic. Clinical trials take year to complete. But Rutgers, a nationally recognized comprehensive cancer center, has the in-house expertise to move faster, said Rutgers Cancer Institute Director Steven K. Libutti, who is overseeing the trial. To read the full article.
Recent Posts
- New NJACTS Publication
- Scientists Discover Immune Cell Networks Driving Deadly Lung Disease.
- Special Type of Fat Tissue Could Help Maintain Exercise Capacity in Aging.
- Fruit Fly Research Led NJIT Scientists and Edison Teens to Better AI Habits on Supercomputers.
- Biologist Pabitra Sahoo and His Research Team Unlock Clues to Repairing Damaged Nerves.
Categories
- Community (2,190)
- Covid (983)
- CTO Events (6)
- News (2,797)
- Pilots (21)